Compare KOP & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOP | ALLO |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 784.7M | 707.6M |
| IPO Year | 2005 | 2018 |
| Metric | KOP | ALLO |
|---|---|---|
| Price | $50.31 | $1.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | ★ $52.50 | $8.35 |
| AVG Volume (30 Days) | 140.4K | ★ 8.3M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | 11.38 | ★ 34.09 |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $1,879,300,000.00 | N/A |
| Revenue This Year | $2.91 | N/A |
| Revenue Next Year | $1.86 | $142,416.42 |
| P/E Ratio | $141.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.00 | $0.99 |
| 52 Week High | $52.25 | $4.46 |
| Indicator | KOP | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 65.29 | 31.83 |
| Support Level | $34.69 | $1.56 |
| Resistance Level | N/A | $1.92 |
| Average True Range (ATR) | 1.74 | 0.11 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 66.41 | 8.26 |
Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).